26th Annual Scientific Assembly

AAEM/JEM Resident and Student Research Competition

This competition is designed to recognize outstanding research achievements by residents and students in emergency medicine.

 

Competition Schedule

Monday, April 20, 2020 | 3:30pm-5:30pm | Valley of the Sun E

3:30pm-3:35pm	Welcome
3:35pm-3:50pm	Recognition of Sepsis in the ED When Diagnosed within 48 hours of Hospitalization Gerald Boley, MD
3:50pm-4:05pm	Comparison of Nebulized Ketamine at Three Different Doses for Acute and Chronic Pain in the ED Mahlaqa Butt
4:05pm-4:20pm	Emergency Department versus Community Clinic Screening on Hepatitis C Linkage to Care Austin T. Jones, MPHTM
4:20pm-4:35pm	Slack® Intern Curriculum: Self-Reported Preparedness for Residency, an ACGME Milestone-Based Study Mary E. McLean, MD
4:35pm-4:50pm	Evaluation of Chest X-ray Utilization in the Emergency Department for Non-traumatic Chest Pain Garrett Rucker
4:50pm-5:05pm	Cardiac Stress Test Utilization and Outcomes in the Emergency Department Observation Unit Jinal Sheth, MD
5:05pm-5:20pm	Judges' Deliberation

*This is not an educational track and there will be no CME for these sessions. AAEM membership is a pre-requisite for participation.

 

Eligibility for Awards

The top 6 abstracts will be selected for oral presentation at AAEM20. All other abstract submissions are invited to display their research as a poster. The presenter of the oral abstract judged to represent the most outstanding research achievement will receive a $3,000 honorarium, while second and third place will receive $1,500 and $500 honoraria, respectively.

 

Abstract Submission Instructions

Please read the abstract submission instructions carefully. The deadline and space requirements are strictly enforced in order to give all authors an equal opportunity to submit their data in the same amount of space and under the same time constraints.

1. Resident or Medical Student Status — In order to be eligible for consideration, the first author and principal investigator of each abstract submitted must be either a (1) resident in an ACGME, AOA, or ACGME-I accredited emergency medicine training program or (2) medical student in an LCME/COCA accredited institution with a strong interest in emergency medicine as a future profession, or a medical student with a strong interest in emergency medicine whose country is found within the Directory of Organizations that Recognize/Accredit Medical Schools (DORA). To verify this, you must submit the name of the appropriate designated official (e.g., program director, dean).
    
2. Submission Deadline
   • Electronic submissions will be accepted beginning September 9, 2019.
   • Abstract receipt deadline for electronic submission is 11:59pm CST on November 4, 2019.
      
3. There is no fee for submitting an abstract. All abstracts must be submitted and presented in English.
    
4. You must submit both a blind and formal version of your abstract.
    
5. If you have questions regarding the abstract submissions for the 26th Annual Scientific Assembly, please call AAEM at (800) 884-2236 or email Rebecca Sommer at rsommer@aaem.org.

 

Competitions are now closed.

 

Abstract Submission Guidelines

Presenting Author Information
You will need to submit the presenting author’s name, address, telephone, and fax numbers, as well as an email address. Only the presenting author listed on the submission form will be notified of abstract acceptance. The presenting author must be a resident or student.

Funding
Indicate what monies have funded the research.

Disclosure of Relevant Financial Relationships
In accordance with the essentials and standards set forth by the Accreditation Council for Continuing Medical Education, as well as guidelines proposed by the Food and Drug Administration and endorsed by the American Medical Association, an author with a conflict of interest with the content of their abstract must disclose that conflict prior to presentation. A conflict of interest includes, but is not limited to, any relevant financial relationship in a company, product or procedure mentioned in the abstract or in the presentation to be given at the conference. The authors must complete the disclosure form included in the electronic submission. A conflict in and of itself will not eliminate an abstract from consideration.

Previous Presentations of Abstracts
No abstract published as an article on or before October 1, 2019, may be submitted for this competition. Abstracts that have been presented at the national meetings of other organizations should not be submitted for consideration. You cannot submit the same abstract for this and the AAEM/RSA & WestJEM Population Health Research Competition.

Informed Consent
Any studies involving human subjects must conform to the principles of the Declaration of Helsinki of the World Medical Association (Clinical Research 1966; 14:103) and must meet all the requirements governing informed consent of the country in which the research was performed.

Abstract Publication
Oral abstracts presented at AAEM’s 26th Annual Scientific Assembly may be published in a summer 2020 issue of the Journal of Emergency Medicine. Ownership of abstracts not accepted reverts to the authors.

Use of Abstracts for Education
Submitters will be asked for permission for AAEM to use accepted abstracts for online continuing medical education purposes. All authors and contributors will be appropriately credited.

Notification of Abstract Selection
The presenting author of all abstracts submitted by November 4, 2019, will receive notification of acceptance or rejection in February 2020.

Withdrawals and Revisions

Withdrawals and revisions must be received in writing to Rebecca Sommer at rsommer@aaem.org by November 11, 2019. No changes can be submitted after that date.

Abstract Formatting

1. Use 12-point Times New Roman (or similar) type. Limit text to 2,500 characters, including spaces, and single space all text in the body of the abstract.
    
2. Do not indent the title. Capitalize only the first letter of each word in the title. List author names using initials only for first and middle names. Underline author names continuously. Include institution, city, and state where research was performed. When submitting the blind copy, omit author names, institution, city, state or any other identifier where research was performed. Omit degrees, titles, institutional appointments, street addresses, and ZIP codes. Single space entire abstract. The left-hand margin of the abstract’s text should be perfectly aligned.
    
3. Use of abbreviations — The use of standard abbreviations is desirable. A special or unusual abbreviation should be placed in parentheses after the first appearance of the full word it represents. Numerals rather than words should indicate numbers, except to begin sentences.
    
4. Use of drug names — Each time a proprietary drug name is used in the abstract, the first letter is capitalized. Nonproprietary (generic) drug names are preferred and are not capitalized.
    
5. Structuring the abstract — Structured abstracts facilitate explicit presentation of critical information and objective assessment of scientific validity. Each abstract should include the following topic headings. It is not necessary to begin a new line or leave extra space between topic headings.

Objectives: A precise statement of the purpose of the study or the pre-study hypothesis. This may be preceded by a brief introduction summarizing past work or relevant controversies that place the study in perspective.

Methods: A brief statement of the methods used, including pertinent information about the study design, setting, participants, subjects, interventions, and observations.

Results: A summary of the results presented in sufficient detail to support the conclusions.

Conclusions: Conclusions should be succinctly stated and firmly supported by the data presented. Note important limitations.

 

1^st Place Submission from the 25^th Annual Scientific Assembly

Utilization Of Tranexamic Acid In Civilian Adult Trauma Resuscitation In The Hospital Setting

Salameh J^a, Dong F^a, Mousselli M^a, Toy J^a, Massoud R^a, Chandowani D^a,e, O’Bosky K^b, Luo-Owen X^b, Wong D^c,e, Vara R^c, Comunale M^d,e, Neeki MM^a,e.

^aDepartment of Emergency Medicine, Arrowhead Regional Medical Center, Colton, CA

^bDepartment of General Surgery, Loma Linda University Medical Center, Loma Linda, CA

^cDepartment of Surgery, Arrowhead Regional Medical Center, Colton, CA

^dDepartment of Anesthesia, Arrowhead Regional Medical Center, Colton, CA

^eCalifornia University of Sciences and Medicine, Colton, CA

 

Funding: No funding was received for this project.  

Conflicts of Interest: By the AAEM abstract submission requirements, all authors are required to disclose all affiliations, funding sources and financial or management relationships that could be perceived as potential sources of bias. No author has professional or financial relationships with any companies that are relevant to this study. There are no conflicts of interest or sources of funding to declare

Objectives: Trauma can pose a severe threat to life and accounts for more than 5.8 million deaths worldwide. Trauma can rapidly lead to coagulopathies causing hemorrhagic shock and death. This study aims to evaluate the safety and efficacy of tranexamic acid (TXA) use in the hospital setting for cases of traumatic hemorrhagic shock.

Methods: Patients from 2 different trauma centers who sustained blunt or penetrating trauma with signs of hemorrhagic shock from March 2015 through June 2018 were considered for TXA treatment. A retrospective control group was formed from patients seen in the past five years who were not administered TXA and matched based on age, gender, ISS, and mechanism of injury. The primary outcome of this study was mortality measured at 24 hours, 48 hours, and 28 days. Secondary outcomes included total blood products, hospital length of stay (LOS), ICU LOS, and adverse events.

Results: Both the hospital TXA and control cohorts consisted of 280 patients. The hospital TXA group had statistically significant lower mortality at 28 days (1.1% vs 5%, p=0.0067); used fewer units of blood products (median of 4 vs 7 units p=0.0005); and had a shorter hospital LOS (median of 7 vs 12 days, p<0.0001). There was no significant difference in adverse effects for TXA versus control. Subgroup analyses were conducted on patients who had and ISS ≥16, and those transfused ≥10 units of blood. The ISS ≥16 subgroup showed a statistically significant lower mortality at 28 days for TXA compared to control. While not significant, those transfused ≥10 units of blood showed a trend towards decreased mortality for TXA versus control.

Conclusions: This study identified a statistically significant reduction in mortality at 28 days after TXA administration in trauma patients, and a trend towards decreased mortality at 24 hours, and 48 hours. Our study shows that TXA may be used safely and efficaciously for trauma-induced hemorrhagic shock in the hospital trauma system.